This document provides supplementary guidance on specific topics for the allergenicity risk assessment of genetically modified plants. In particular, it supplements general recommendations outlined in previous EFSA GMO Panel guidelines and Implementing Regulation (EU) No 503/2013. The topics addressed are non-IgE-mediated adverse immune reactions to foods, in vitro protein digestibility tests and endogenous allergenicity. New scientific and regulatory developments regarding these three topics are described in this document. Considerations on the practical implementation of those developments in the risk assessment of genetically modified plants are discussed and recommended, where appropriate. (C) 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority

Iron deficiency is a common health problem. The most severe consequence of this disorder is iron deficiency anemia (IDA), which is considered the most common nutritional deficiency worldwide. Newborn piglets are an ideal model to explore the multifaceted etiology of IDA in mammals, as IDA is the most prevalent deficiency disorder throughout the early postnatal period in this species and frequently develops into a critical illness. Here, we report the very low expression of duodenal iron transporters in pigs during the first days of life. We postulate that this low expression level is why the iron demands of the piglet body are not met by iron absorption during this period. Interestingly, we found that a low level of duodenal divalent metal transporter 1 and ferroportin, two iron transporters located on the apical and basolateral membrane of duodenal absorptive enterocytes, respectively, correlates with abnormally high expression of hepcidin, despite the poor hepatic and overall iron status of these animals. Parenteral iron supplementation by a unique intramuscular administration of large amounts of iron dextran is current practice for the treatment of IDA in piglets. However, the potential toxicity of such supplemental iron implies the necessity for caution when applying this treatment. Here we demonstrate that a modified strategy for iron supplementation of newborn piglets with iron dextran improves the piglets' hematological status, attenuates the induction of hepcidin expression, and minimizes the toxicity of the administered iron. (Am J Pathol

Lysine is an essential amino acid for all animal species; it is the first limiting amino acid in swine nutrition and the second limiting amino acid in poultry nutrition. L-Lysine and its salts are widely used in the feed industry to optimise dietary protein.Neither the production strain nor its recombinant DNA was detected in any of the final products. The final products do not raise any safety concern with regard to the genetic modifications.Concentrated liquid L-lysine (base), concentrated liquid L-lysine HCl and L-lysine HCl technically pure are considered safe for target species when supplemented in appropriate amounts.Lysine produced by E. coli (FERM BP-10941) is not genotoxic and the results of subchronic studies do not indicate any specific concerns. As there are no lysine metabolites associated with safety concerns in the animal tissues and products, the FEEDAP Panel considers that the use of L-lysine and its hydrochloride salts in animal feed does not pose a risk for the consumer.Concentrated liquid L-lysine (base), concentrated liquid L-lysine HCl and L-lysine HCl technically pure are not considered to have the potential to cause respiratory toxicity, skin or eye irritation or skin sensitisation, but respiratory sensitisation cannot be excluded.L-Lysine is a substance naturally occurring in bacteria, plants and animals. The use of L-lysinecontaining feed additives does not represent a risk to the environment.Concentrated liquid L-lysine (base), concentrated liquid L-lysine HCl and L-lysine HCl technically pure are considered equivalent in terms of L-lysine availability to the target animals. The efficacy of supplementing L-lysine and its hydrochloride salts is extensively demonstrated in the literature for mammals (except ruminants), poultry and fish, including its use in a liquid or a powder form. Therefore, it does not require any further demonstration. Response in ruminants requires some degree of protection of L-lysine from ruminal degradation.

The aim of this investigation was to compare the influence of naringin versus red grapefruit juice on plasma lipid levels and plasma antioxidant activity in rats fed cholesterol-containing and cholesterol-free diets. The antioxidant activity of a correlated quantity of red grapefruit juice was higher than that of naringin. Forty-two male Wistar rats were randomly divided into six groups of 7 named control, naringin, grapefruit, Chol, Chol/naringin, and Chol/grapefruit. The rats of the control group were fed basal diet (BD) and 1-2 mL of distilled water. To the BD of the other five groups were added 0.46-0.92 mg of naringin dissolved in 1-2 mL of distilled water (naringin), 1-2 mL of red grapefruit juice (grapefruit), 1% of nonoxidized cholesterol (NOC) and 1-2 mL of distilled water (Chol), 1% of NOC and 0.46-0.92 mg of naringin in 1-2 mL of water (Chol/naringin), and 1% of NOC and 1-2 mL of red grapefruit juice (Chol/grapefruit). After 30 days of different feeding, it was found that diets supplemented with red grapefruit juice and to a lesser degree with naringin improved the plasma lipid levels mainly in rats fed cholesterol and increased the plasma antioxidant activity. In conclusion, naringin is a powerful plasma lipid lowering and plasma antioxidant activity increasing flavonone. However, fresh red grapefruit is preferable than naringin: it more effectively influences plasma lipid levels and plasma antioxidant activity and, therefore, could be used as a valuable supplement for disease-preventing diets.